CN102782123B - 用于抑制肿瘤细胞增殖的改进的组合物 - Google Patents

用于抑制肿瘤细胞增殖的改进的组合物 Download PDF

Info

Publication number
CN102782123B
CN102782123B CN201180008012.3A CN201180008012A CN102782123B CN 102782123 B CN102782123 B CN 102782123B CN 201180008012 A CN201180008012 A CN 201180008012A CN 102782123 B CN102782123 B CN 102782123B
Authority
CN
China
Prior art keywords
cells
dcs
cell
pro
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180008012.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN102782123A (zh
Inventor
亚历克斯·卡森·帕拉
本·安德森
安娜卡琳·沃尔格伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mendus AB
Original Assignee
Immunicum AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunicum AB filed Critical Immunicum AB
Publication of CN102782123A publication Critical patent/CN102782123A/zh
Application granted granted Critical
Publication of CN102782123B publication Critical patent/CN102782123B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A61K40/4532—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201180008012.3A 2010-02-10 2011-02-10 用于抑制肿瘤细胞增殖的改进的组合物 Expired - Fee Related CN102782123B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30315310P 2010-02-10 2010-02-10
US61/303,153 2010-02-10
SE1050133 2010-02-10
SE1050133-6 2010-02-10
PCT/EP2011/051952 WO2011098516A1 (en) 2010-02-10 2011-02-10 Improved composition for inhibiting tumor cell proliferation

Publications (2)

Publication Number Publication Date
CN102782123A CN102782123A (zh) 2012-11-14
CN102782123B true CN102782123B (zh) 2016-05-11

Family

ID=43903832

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180008012.3A Expired - Fee Related CN102782123B (zh) 2010-02-10 2011-02-10 用于抑制肿瘤细胞增殖的改进的组合物

Country Status (13)

Country Link
US (1) US9034317B2 (enExample)
EP (1) EP2534242B1 (enExample)
JP (1) JP5855018B2 (enExample)
KR (1) KR101770785B1 (enExample)
CN (1) CN102782123B (enExample)
BR (1) BR112012019267B1 (enExample)
DK (1) DK2534242T3 (enExample)
ES (1) ES2581277T3 (enExample)
HU (1) HUE028352T2 (enExample)
PL (1) PL2534242T3 (enExample)
RU (1) RU2565542C2 (enExample)
SI (1) SI2534242T1 (enExample)
WO (1) WO2011098516A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102148051B1 (ko) * 2012-12-18 2020-08-25 이뮤니쿰 에이비 동종이계 공여자로부터 단핵세포의 동시-분화
KR102873947B1 (ko) * 2015-05-07 2025-10-22 베이롤 칼리지 오브 메드신 수지상 세포 면역요법
CN105695403A (zh) * 2015-12-31 2016-06-22 深圳市中美康士生物科技有限公司 一种杀伤性免疫细胞的培养方法及其应用
CN105462926A (zh) * 2015-12-31 2016-04-06 深圳市中美康士生物科技有限公司 一种免疫细胞瘤苗的制备方法及其应用
CN107574149B (zh) * 2016-07-05 2022-02-18 上海细胞治疗研究院 一种树突状细胞的促成熟方法及其用途
CN106085960A (zh) * 2016-07-28 2016-11-09 广州赛莱拉干细胞科技股份有限公司 一种培养dc细胞的培养基及培养方法
EP3516045A1 (en) * 2016-09-23 2019-07-31 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods of preparing an isolated population of dendritic cells and methods of treating cancer using same
GB201711379D0 (en) * 2017-07-14 2017-08-30 Univ Cape Town Maturation of dendritic cells
EP3460052B1 (en) * 2017-09-20 2019-10-30 Immunicum AB Improved allogeneic dendritic cells for use in cancer treatment

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007110240A1 (en) * 2006-03-28 2007-10-04 Helmholtz Zentrum München - Deutsches Forschungszentrum Für Umwelt Und Gesundheit Gmbh Compositions for the preparation of mature dendritic cells
WO2008110569A1 (en) * 2007-03-12 2008-09-18 Bioneer A/S Method for determination of immunomodulatory effect
CN101481677A (zh) * 2009-01-22 2009-07-15 复旦大学附属华山医院 体外刺激树突状细胞成熟的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040214783A1 (en) * 2002-05-08 2004-10-28 Terman David S. Compositions and methods for treatment of neoplastic disease
EP2260861A1 (en) * 2002-12-06 2010-12-15 NorthWest Biotherapeutics, Inc. Administration of dendritic cells partially matured in vitro for the treatment of tumors
JP2010539993A (ja) 2007-10-08 2010-12-24 イントレキソン コーポレーション 遺伝子操作した樹状細胞および癌の治療のための使用
WO2010065876A2 (en) * 2008-12-06 2010-06-10 The Board Of Regents Of The University Of Texas System Methods and compositions related to th-1 dendritic cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007110240A1 (en) * 2006-03-28 2007-10-04 Helmholtz Zentrum München - Deutsches Forschungszentrum Für Umwelt Und Gesundheit Gmbh Compositions for the preparation of mature dendritic cells
WO2008110569A1 (en) * 2007-03-12 2008-09-18 Bioneer A/S Method for determination of immunomodulatory effect
CN101481677A (zh) * 2009-01-22 2009-07-15 复旦大学附属华山医院 体外刺激树突状细胞成熟的方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Interferon γ dose-dependently inhibits prostaglandin E2-mediated dendritic-cell-migration towards secondary lymphoid organ chemokines;John Alder, et al.;《Vaccine》;20060718;第24卷;7087-7094 *
Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration;A. C. Inge Boullart, et al.;《Cancer Immunol Immunother》;20080306;第57卷;1589-1597 *
Recruitment and Activation of Natural Killer Cells In vitro by a Human Dendritic Cell Vaccine;Karin Gustafsson, et al.;《Cancer Research》;20080715;第68卷(第14期);5965-5971 *
体外诱导培养健康成人外周血单核细胞源树突状细胞及鉴定;叶双樱,等;《浙江中西医结合杂志》;20091231;第19卷(第12期);740-742 *

Also Published As

Publication number Publication date
KR20120114358A (ko) 2012-10-16
SI2534242T1 (sl) 2016-08-31
HUE028352T2 (en) 2016-12-28
WO2011098516A1 (en) 2011-08-18
KR101770785B1 (ko) 2017-08-23
US20120328662A1 (en) 2012-12-27
RU2565542C2 (ru) 2015-10-20
JP2013519363A (ja) 2013-05-30
CN102782123A (zh) 2012-11-14
JP5855018B2 (ja) 2016-02-09
EP2534242B1 (en) 2016-04-20
EP2534242A1 (en) 2012-12-19
BR112012019267A2 (pt) 2020-10-06
RU2012137173A (ru) 2014-03-20
US9034317B2 (en) 2015-05-19
BR112012019267B1 (pt) 2022-03-03
PL2534242T3 (pl) 2016-11-30
DK2534242T3 (en) 2016-07-18
ES2581277T3 (es) 2016-09-05

Similar Documents

Publication Publication Date Title
CN102782123B (zh) 用于抑制肿瘤细胞增殖的改进的组合物
Liau et al. Treatment of intracranial gliomas with bone marrow—derived dendritic cells pulsed with tumor antigens
CN102597222B (zh) 用于增殖抗原特异性t细胞的方法
CN100337686C (zh) 从前体产生加载有抗原的树突细胞疫苗的快速一步法
AU758622B2 (en) Method for activating natural killer (NK) cells
CN103502439A (zh) 用于抗原特异性t细胞增殖的方法
AU2008265911A1 (en) Use of TLR agonists and/or type 1 interferons to alleviate toxicity of TNF-R agonist therapeutic regimens
CN105007930B (zh) 用于治疗疾病的同种异体自噬体富集组合物
JP2022552200A (ja) 樹状細胞およびＴ細胞の活性化を増強するためのならびにＴＨ－１免疫応答を誘導するためのｉｎ ｖｉｔｒｏの方法および組成物
Khamisabadi et al. Listeria monocytogenes activated dendritic cell based vaccine for prevention of experimental tumor in mice
JP7146732B2 (ja) 宿主抗原提示並びに宿主抗腫瘍及び抗病原体免疫を最適化するためのプラットフォーム及び方法
US10716810B2 (en) Canine autologous immunotherapy using dendritic cell induced cancer killing immunocytes
WO2016135286A1 (en) Method for stimulating dendritic cells (dcs)
Pham Regulation of memory CD8 T cell differentiation
van den Ancker et al. R848 enhances uptake of leukemic cells by DC but
US20120076827A1 (en) Compositions and methods for generating an immune response in a subject
HK1089336A (en) Rapid one-step method for generation of antigen loaded dendritic cell vaccine from precursors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160511

CF01 Termination of patent right due to non-payment of annual fee